Speaking to CNBC-TV18 on the impact of the surprise audit on the company, Sarabjit Kour Nangra, Angel Broking advises investors not to panic and wait till the details of the audit report are released. According to Nangra, Sun's merger with Ranbaxy ... Moneycontrol.com, 2 weeks ago
'Accumulate' Cipla with target at Rs 480: Angel Broking - Myiris, 1 month ago
Buy Infosys with target price of Rs 4245: Angel Broking - Money Control, 2 months ago
3 images for "sarabjit kour nangra"
Wipro has started a 3 year exercise to become a leaner company. The company is in the process to slim its workflow down by about a third without resorting to mass layoffs, through deploying automation. The company is looking at being around ...MyIris, 1 day ago Angel Broking maintains 'Buy' on Ipca Laboratories MyIris, 1 week ago
The rupee plummeted to a seven-month low on Monday, making stock investors nervous, but the export-oriented pharma and IT stocks rallied. The market was cautious also because of Tuesday’s money policy review, in which the Reserve Bank of India is widely ...The Financial Chronicle, 2 days ago
Sun Pharmaceuticals plans to focus on dermatology, post its merger with Ranbaxy Labs, expected to be completed by 2014. The company has lined-up a strategy to make dermatology its biggest segment and expects almost 38-40% of US sales to come from ...MyIris, 2 days ago Sun tanks 6% as Halol unit comes under cloud DNA India, 2 weeks ago Sun Pharma falls 4% on surprise inspection reports Business Today India, 2 weeks ago Sun Pharma shares dip on surprise audit by USFDA at Halol plant IndiaVision, 2 weeks ago
The decision of the National Pharmaceutical Pricing Authority to withdraw the guidelines for price control on 108 drugs has been welcomed by the pharmaceutical industry. The decision of the National Pharmaceutical Pricing Authority (NPPA) to ...The Hindu, 2 days ago Govt clips NPPA's sweeping powers to control drug prices Hindu Business Line, 1 week ago NPPA price control buzz positive for Sanofi, Zydus, Ranbaxy:Angel Broking MyIris, 1 week ago Sanofi India surges as NPPA withdraws price control guidelines Business Standard India, 1 week ago
The pharma industry in India heaved a sigh of relief when the government decided to withdraw a special power that had earlier allowed the National Pharma Pricing Authority to slash prices of several drugs, mostly under the diabetes and cardiac ...Financial Chronicle, 3 days ago Sanofi India surges as govt withdraws NPPA's power on pricing of non-essential drugs Business Standard India, 1 week ago
Sanofi India has gained 4%, extending its 11% rally in the previous session, as the company would benefit the most after the government withdrew National Pharmaceutical Pricing Authority's power that permitted it to fix prices of non-essential ...Business Standard India, 1 week ago
The National Pharmaceutical Pricing Authority (NPPA) on Monday announced the withdrawal of an internal guideline to fix prices of 108 non-scheduled formulations. Though the decision is disappointing for consumers, mainly cardiac and diabetes ...DNA India, 1 week ago NPPA withdraws internal g'lines on drug pricing Express Pharma, 1 week ago
Tech Mahindra today said it has signed a letter of agreement with Finland-based Ahlstrom to manages its information technology solutions. The multi-year, multi-million Euro contract with Ahlstrom is aimed at increasing efficiency, harmonise ...Business Standard India, 1 week ago Angel Broking recommends 'Accumulate' on Tech Mahindra MyIris, 1 week ago
Sanofi,one of theleading pharmaceutical companies, witnessed a sharp rise in share prices on Tuesday. The company's sharesjumpedafter the National Pharmaceutical Pricing Authority (NPPA) has withdrawn guidelines for price control of 108 ...New Indian Express, 1 week ago
on your WebpageAdd Widget >Get your members hooked!